# Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma

Source: https://onco.cc/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022/  
OnCo record `paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Review on Ciltacabtagene autoleucel in Multiple myeloma, in Frontiers in immunology (2022), one of the most cited Europe PMC records with Ciltacabtagene autoleucel in its title.

## Summary

Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer cells in B cell malignancies, such as multiple myeloma (MM). It is a second-generation CAR that is outfitted with an ectodomain comprising two BCMA-binding single chain variable fragment (ScFv) domains, a transmembrane domain, and an endodomain possessing CD3ζ and 4-1BB. Cilta-cel is an autologous, gene-edited CAR T-cell that is prepared by collecting and modifying the recipient's T-cells to create a patient personalized treatment in the laboratory to be infused back. This CAR T-cell product exceptionally entails CARs with two BCMA-targeting single-domain antibodies that detect two epitopes of BCMA expressed on the malignant cells of MM. Cilta-cel is the current addition to the treatment armamentarium of relapsed or refractory (r/r) MM after its approval by the FDA on February 28, 2022, based on the results of the Phase 1b/2 CARTITUDE-1 study. It was the second approved anti-BCMA CAR T-cell product after idecabtagene vicleucel (ide-cel) to treat myeloma patients. It induces early, deep, and long-lasting responses with a tolerable safety profile in r/r MM. Cilta-cel-treated myeloma patients may potentially experience adverse effects ranging from mild to life-threatening, but they are mostly manageable toxicities. Besides, it has a consistent safety profile upon a longer follow-up of patients. Cilta-cel generally outperforms ide cel in terms of efficacy in MM, but shows comparable adverse events. This review highlights the current updates on cilta-cel efficacy, adverse events, comparison with ide-cel, and its future direction in the treatment of MM.

Indexed on Europe PMC as PubMed record 36119032 (DOI 10.3389/fimmu.2022.991092). Its title names Ciltacabtagene autoleucel and its text names Multiple myeloma; PubMed types it as a review (review-article, Review). It was matched automatically to the idea "One CAR-T infusion instead of autologous transplant" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Frontiers in immunology
- Year: 2022
- DOI: 10.3389/fimmu.2022.991092
- Authors: Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, et al.
- What it means: One of the most cited reviews Europe PMC returns for Ciltacabtagene autoleucel in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by Ciltacabtagene autoleucel in the title and Multiple myeloma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; A review summarises other studies; the primary reports it cites are the evidence.

## Sources

- Front Immunol 2022: https://doi.org/10.3389/fimmu.2022.991092
- PubMed: https://pubmed.ncbi.nlm.nih.gov/36119032/
- Europe PMC: https://europepmc.org/article/MED/36119032

## Connected records

- ideas: [One CAR-T infusion instead of autologous transplant](https://onco.cc/ideas/idea-car-t-replaces-transplant/)

---
JSON: https://onco.cc/api/v1/entities/paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022.json